zepbound semaglutide or tirzepatide Beats Wegovy for Weight Loss in First Head-to-Head Trial Zepbound vs Ozempic - Bariatric

Cardiovascular Benefits The SELECT trial showed Wegovy reduces major cardiovascular events by 20% in people with obesity and heart disease (but without diabetes)

Data extraction and risk of bias assessment Two authors independently completed the literature search, data extraction, and quality evaluation of the included studies according to predetermined criteria

Clinical trials have demonstrated cardiovascular benefits in certain patient populations, with Ozempic specifically indicated for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and Wegovy indicated for cardiovascular risk reduction in adults with established cardiovascular disease who have either obesity or overweight

Prepare the Vials: Remove the plastic safety caps from both vials